Generate Biomedicines (NASDAQ:GENB) Coverage Initiated by Analysts at Morgan Stanley

Morgan Stanley assumed coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research report released on Tuesday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $20.00 price objective on the stock.

Other equities research analysts have also issued reports about the company. The Goldman Sachs Group started coverage on Generate Biomedicines in a research report on Tuesday. They set a “buy” rating and a $26.00 price target on the stock. Wall Street Zen raised Generate Biomedicines to a “hold” rating in a research report on Saturday, March 14th. Guggenheim assumed coverage on shares of Generate Biomedicines in a report on Tuesday. They set a “buy” rating and a $30.00 target price on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Generate Biomedicines in a research report on Tuesday. They issued an “overweight” rating on the stock. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Generate Biomedicines currently has a consensus rating of “Buy” and an average price target of $25.00.

Generate Biomedicines Stock Performance

Shares of NASDAQ:GENB opened at $12.03 on Tuesday. Generate Biomedicines has a 52-week low of $11.00 and a 52-week high of $15.32.

More Generate Biomedicines News

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: Piper Sandler initiated coverage with an “overweight” rating and a $24 price target (roughly +99% vs current levels). Benzinga
• Positive Sentiment: Morgan Stanley started coverage with an “overweight” and $20 price target (~+66%). Benzinga TickerReport
• Positive Sentiment: Goldman Sachs initiated with a “buy” and a $26 price target (~+116%). Benzinga
• Positive Sentiment: Guggenheim initiated coverage with a “buy” and a $30 price target (~+149%). Benzinga
• Positive Sentiment: Cantor Fitzgerald added coverage with an “overweight” rating. Benzinga
• Neutral Sentiment: Short-interest entries for late March show reported increases, but the published figures contain zeros and NaN values (short interest = 0 shares; days-to-cover = NaN), indicating data errors or unreliable reporting — treat these headlines as ambiguous until corrected by exchanges or the data provider.
• Neutral Sentiment: Trading volume is below average today (intraday volume lower than the 12-month average), which can amplify price moves and increase volatility on mixed news.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.